About Us

EXECUTIVE SUMMARY

PharmaEngine, Inc. is a biopharmaceutical company established in February 2003 with funding from TTY Biopharm and Taiwanese venture capital companies. PharmaEngine is a networked pharma company that operates according to a “No Research, Development Only (NRDO)” model. It is led by Dr. Grace Yeh and supported by a strong network of reputable advisors and consultants worldwide.

PharmaEngine focuses on the development of new drugs for the treatment of cancer diseases. There are 3 projects in the pipeline. ONIVYDE® (PEP02, MM-398, nal-IRI), a new formulation of an anti-cancer drug (irinotecan) for the patients with gemcitabine-treated metastatic pancreatic cancer, was approved by both the US FDA and Taiwan FDA in 2015, European Medicines Agency (EMA) in 2016, Korea MFDS and Singapore HAS in 2017. PEP503 (NBTXR3), a nanoparticle working as a radio-enhancer, is in a positive global pivotal trial of soft tissue sarcoma, the other ongoing studies are in Phase I/II trial in head and neck cancerand rectal cancer in Taiwan. PEP06, a new chemical entity (NCE) for cancer treatment, is currently in the pre-clinical stage.

In April 2017, Ipsen S.A., a French company, completed the acquisition of ONIVYDE® from Merrimack Pharmaceuticals, Inc. for the US marketing and sales and became the new corporate partner of PharmaEngine, Inc. PharmaEngine and Ipsen are now working closely to complete NDA for worldwide approval of ONIVYDE® in the post-gemcitabine metastatic pancreatic cancer and also life cycle management of ONIVYDE® of new indications.

Meanwhile, PharmaEngine continuously puts the best efforts to move forward the clinical and pre-clinical developments of PEP503 (NBTXR3) and PEP06. Furthermore, PharmaEngine is actively seeking to in-license new projects for preclinical/clinical development and commercialization.

BUSINESS MODEL

PharmaEngine has adapted the “no research, development only model (NRDO)” as well as “networked pharma model” for new drug development. We license in drug candidates for drug development, taking them through various stages ranging from preclinical to clinical and further out-licensing.

We are an integrated development company with strong expertise in identifying and executing strategies for drug development that can leverage development resources through collaborative arrangements with partners in our global network.

Discover more on our business model here.

Visit Our History & Milestones

Organization Chart

Audit
Compensation Committee
Audit Committee
Translational Science
Clinical & Regulatory Affairs
Corporate Development
Marketing & Sales
Finance & Administration

PharmaEngine
Inc.

Wholly-owned Subsidiary

The Company established a wholly-owned subsidiary, PharmaEngineEurope Sarl in Paris, France in November 2015. It focuses on the identification and evaluation of new projects.

PharmaEngine
Europe Sarl

Our Partners

Interested in participating on upcoming drug developments?
Let's Talk